Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 606 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Naloxone Clear all
Completed Phase 2 Interventional

Sertraline and Naltrexone for Alcohol Dependence

NCT00000440
View directory record Official record
Conditions
Alcoholism
Interventions
naltrexone (Revia), sertraline (Zoloft)
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Buprenorphine Naltrexone-P1 A-Cocaine

NCT00733720
View directory record Official record
Conditions
Cocaine-related Disorders
Interventions
Suboxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 1, 2026, 10:42 AM EDT
Withdrawn Phase 4 Interventional

Buprenorphine/Naloxone Micro-Dosing for Postoperative Pain Management in Opioid-Tolerant Patients

NCT04771689
View directory record Official record
Conditions
Post-operative Pain
Interventions
Buprenorphine/Naloxone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 1, 2026, 10:42 AM EDT
Completed No phase listed Observational

Critical Respiratory Events in Children Requiring Naloxone: Naloxone Use as Opioid Safety Measure

NCT01860885
View directory record Official record
Conditions
Opioid Induced Respiratory Depression
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Day and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Sep 1, 2026, 10:42 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease

NCT01810185
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
Low dose naltrexone, Placebo
Drug
Lead sponsor
Santa Barbara Cottage Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Sep 1, 2026, 10:42 AM EDT
Recruiting Phase 4 Interventional

Low Dose Naltrexone for Pain in Patients With HIV

NCT05537935
View directory record Official record
Conditions
Human Immunodeficiency Virus, Chronic Neuropathic Pain
Interventions
Low Dose Naltrexone
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 1, 2026, 10:42 AM EDT
Withdrawn Phase 2 Interventional

Olanzapine in OUD Patients

NCT05179772
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Olanzapine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Sep 1, 2026, 10:42 AM EDT
Not yet recruiting Phase 4 Interventional

Examining Analgesic Synergy and Efficacy in Trauma Care

NCT07435077
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine, Oxycodone
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

Oral vs. Injectable Naltrexone for Hospitalized Veterans With Alcohol Dependence

NCT01856712
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Naltrexone
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 1, 2026, 10:42 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)

NCT07221565
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases, Chronic Inflammatory Syndromes, Immune Dysregulation
Interventions
Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN)
Device · Drug
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects

NCT02391571
View directory record Official record
Conditions
Withdrawal Symptoms
Interventions
Oxycodone/Naltrexone Capsules, Oxycodone, Placebo
Drug
Lead sponsor
Elite Laboratories, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy Volunteers

NCT02750748
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Naltrexone, Intravail
Drug · Other
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Early Phase 1 Interventional Results available

Chronic Low Back Pain and Meditation

NCT04034004
View directory record Official record
Conditions
Pain
Interventions
Mindfulness, Naloxone, Saline, Meditation
Behavioral · Drug · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 1, 2026, 10:42 AM EDT
Not listed Phase 4 Interventional

Bridging ED to Outpatient AUD Therapy With Naltrexone

NCT05228418
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Naltrexone Pill
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 2 Interventional

Trial of Naltrexone and Dextromethorphan for Gulf War Illness

NCT02206490
View directory record Official record
Conditions
Gulf War Illness
Interventions
naltrexone, Dextromethorphan
Drug
Lead sponsor
East Carolina University
Other
Eligibility
18 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Sep 1, 2026, 10:42 AM EDT
Completed No phase listed Observational

Using mHealth to Aid Opioid Medication Adherence Pilot Study

NCT02017041
View directory record Official record
Conditions
Opioid Dependence
Interventions
Medsignals, smartphone app
Device
Lead sponsor
Care Team Solutions
Industry
Eligibility
21 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Sep 1, 2026, 10:42 AM EDT
Withdrawn Phase 3 Interventional

Evaluation of BEMA® Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects

NCT01713803
View directory record Official record
Conditions
Opioid Dependence
Interventions
Buprenorphine and naloxone
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)

NCT05090280
View directory record Official record
Conditions
Pharmacokinetics
Interventions
PF614 solution, Naltrexone Hydrochloride, Nafamostat Mesylate
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

Double-Blind Naltrexone in Kleptomania

NCT00332579
View directory record Official record
Conditions
Kleptomania
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 28, 2019 · Synced Sep 1, 2026, 10:42 AM EDT
Completed No phase listed Observational

Safety and Efficacy of a Low Dose Naloxone Infusion in NICU Patients

NCT00669175
View directory record Official record
Conditions
Opioid Tolerance, Pain
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
1 Day to 30 Days
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 2 Interventional

HIV Risk Reduction and Drug Abuse Treatment in Malaysia

NCT00383045
View directory record Official record
Conditions
Opiate Dependence
Interventions
Buprenorphine/Subutex, Naltrexone, Drug counseling
Drug · Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 4 Interventional Results available

Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population

NCT02038790
View directory record Official record
Conditions
Opioid Dependence
Interventions
Suboxone Sublingual Film, Zubsolv sublingual tablets
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder

NCT02559973
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
RBP-6000, SUBOXONE Sublingual Film
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neuropeptides in Human Reproduction

NCT01952782
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
Kisspeptin 112-121, Naloxone, GnRH
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Sep 1, 2026, 10:42 AM EDT